Goldman Sachs
CKPT

Goldman Sachs’s Checkpoint Therapeutics CKPT Stock Holding History

Goldman Sachs’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-196,125
Closed -$628K – 6103
2024
Q4 		$628K Buy
+196,125
New +$665K ﹤0.01% 5112
2022
Q2 		– Sell
-16,521
Closed -$292K – 6483
2022
Q1 		$292K Buy
+16,521
New +$355K ﹤0.01% 5675
2021
Q3 		– Sell
-13,009
Closed -$384K – 6253
2021
Q2 		$384K Buy
13,009
+10,529
+425% +$292K ﹤0.01% 5368
2021
Q1 		$78K Sell
2,480
-4,171
-63% -$140K ﹤0.01% 5886
2020
Q4 		$176K Buy
6,651
+4,273
+180% +$108K ﹤0.01% 5127
2020
Q3 		$64K Buy
+2,378
New +$57.1K ﹤0.01% 5151
2020
Q2 		– Sell
-2,288
Closed -$35K – 5233
2020
Q1 		$35K Buy
+2,288
New +$40.5K ﹤0.01% 5085
2018
Q2 		– Sell
-2,145
Closed -$94K – 5691
2018
Q1 		$94K Buy
+2,145
New +$93.1K ﹤0.01% 5305

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Goldman Sachs's CKPT Position: Q1 2025 in Review

Goldman Sachs sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 196,125 shares — an estimated $628K sold.

Goldman Sachs first reported a position in CKPT in Q1 2018 and held it in 8 quarters. The position peaked at $628K in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Goldman Sachs reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 196,125 Checkpoint Therapeutics shares in Q1 2025, an estimated $628K.
  • Goldman Sachs first reported a position in Checkpoint Therapeutics in Q1 2018 and held it in 8 quarters.
  • Goldman Sachs's Checkpoint Therapeutics position peaked at $628K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.